
Veolia launches French battery-metals plant with nearly 7,000‑tonne capacity
The Grand Est site will recover cobalt, nickel and copper from black mass, but Veolia disclosed no investment cost or earnings forecast.

Natural graphite capacity could grow 20 per cent as China retains its dominance and Western tungsten projects face commissioning milestones.

The Grand Est site will recover cobalt, nickel and copper from black mass, but Veolia disclosed no investment cost or earnings forecast.

Selective sampling identified a new skarn target south of Lamb Mountain, but GoldHaven has not dated follow-up work.
Omineca would retain a 50 per cent carried interest and receive half the recovered gold at a base cost of C$1,000 an ounce.
Uranium sales costs averaged US$87.22 per pound, while the producer awaits Texas approvals for extraction targets before year-end.

The 26-patient trial supports a priority review request, but the Nov. 12 release gives no FDA acceptance date or decision deadline.

EsoGuard test volume reached a monthly record in October, while quarterly operating expenses were US$13.5 million.

The partners will combine CPUs, GPUs and adaptive computing, with more details due at Chicago's SC26 conference on Nov. 15 to 20.

True widths are estimated at 70 to 90 per cent of drilled lengths, with assays from 54 holes still pending.
OPG is reassessing Darlington's first SMR budget and schedule, with its assessment due to be substantially complete by mid-2027.
The system supports 150 mm and 200 mm wafers, but the company disclosed no purchase price, delivery date or output target.
Most consolidated cash sits at WhiteFiber, while pledged ether supports borrowing and new project financing remains subject to funding conditions.
The provider's final review confirms the removal, while its public notice gives no dollar estimate of passive-fund selling.
The quantum-computer developer held US$497.1 million in cash and investments as it targeted a larger system for mid-2028.
About 3,000 tonnes are planned for TotalEnergies' Leuna refinery in 2027 as the partners begin testing the integrated supply chain.
The STOXX Europe 600 advanced as AI demand optimism met higher infrastructure spending, with Nvidia results scheduled for Nov. 17.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Prepayments will help fund U.S. enrichment capacity, with enough HALEU for up to five Aurora powerhouses over multiple years.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The orexin-targeting tablet is now available through a specialty pharmacy, following the FDA's Aug. 5 approval.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.
The proposed 1 GW facility accounts for most of the announced budget, but ReNew has disclosed neither financing terms nor a delivery date.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
TNR holders would receive Altius shares and a stake in an Alaska gold spinout, subject to shareholder, court and exchange approvals.

The Nevada project retains late-2027 mechanical completion and a 2028 production ramp-up, with capital needs expected to remain funded.

Full production is targeted for 2028, with Louisiana offering a performance-based grant and the company planning 175 additional jobs.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.

The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.

Operating cash flow reached US$9.5 million as expansion spending eased, but weaker Canadian wholesale pricing reduced cannabis profit.